A randomized controlled trial of combined ivermectin and zinc sulfate versus combined hydroxychloroquine, darunavir/ritonavir, and zinc sulfate among adult patients with asymptomatic or mild coronavirus-19 infection
Conclusion: We demonstrated that both treatment regimens were safe, but both treatment regimens had no virological or clinical benefit. Based on this result and current data, there is no supporting evidence for the clinical benefit of ivermectin for coronavirus-19.
Source: Journal of Global Infectious Diseases - Category: Infectious Diseases Authors: Sireethorn Nimitvilai Yupin Suputtamongkol Ussanee Poolvivatchaikarn Dechatorn Rassamekulthana Nuttawut Rongkiettechakorn Anek Mungaomklang Susan Assanasaen Ekkarat Wongsawat Chompunuch Boonarkart Waritta Sawaengdee Source Type: research
More News: Coronavirus | COVID-19 | Genetics | Hydroxychloroquine | Infectious Diseases | Norvir | Prezista | Respiratory Medicine | SARS | Study | Virology | Zinc